Saturday, February 18, 2017 7:25:42 PM
** Great, I'll buy on the dip.
** We'll win a lawsuit or collect millions from insurance.
I like the attitude.
Lets really look beyond these bight spots.
First, Momenta is responsible for the product configuration and Sandoz is responsible for the Manufacturing and Distribution. There could be future considerations but normally there wouldn't be any liability or insurance at this point. Did Momenta have to pay Sandoz every time the FDA delayed approval because of a science question?
Second, I expect Tuesday's dip to be minor, maybe in the $16 range at most but probably in the $17 range. This would depend on no new info on the CC.
The real dip would occur if someone else received approval prior to Sandoz receiving the FDA approval. Nasty. But of course, you can buy more on that dip.
What kind of 'bright spot' is it that Glatopa, and generic Copaxone will be tainted by this. I'm sure Teva would never bring it up to the Neuro Guys.
While this is not a death sentence by any means, it's not welcome news. The only winner in this mess is TEVA.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM